Arbele Announces Phase I First-in-Human Study of CDH17xCD3 Bispecific T Cell Engager for Treatment of Gastrointestinal Cancers

Arbele, a clinical stage biopharmaceutical company, announced the successful dosing of the first patient in Australia in Phase I Study of ARB202, for the treatment of advanced gastrointestinal cancers patients.